APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Avelumab

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Avelumab Market Outlook and Growth Opportunities 2026

Report ID 173968460423 December 2025198 pages

Choose your research edition.

Industry ResearchAvelumab Industry Research Report 2026105 pages · $2,950 USDIndustry Growth & TrendsGlobal Avelumab Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal Avelumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Avelumab Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Avelumab Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Avelumab market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Avelumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Avelumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Avelumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Avelumab market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Avelumab market include Merck and Pfizer among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Avelumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Avelumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Avelumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Avelumab market size, projected growth trends, production technologies, key applications, and end-use industries.

Avelumab Segment by Company

Merck

Pfizer

Avelumab Segment by Type

By Usage

By Specifications

Avelumab Segment by Application

Merkel-cell Carcinoma

Non-small Cell Lung Carcinoma (NSCLC)

Others

Avelumab Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Avelumab status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Avelumab market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Avelumab significant trends, drivers, influence factors in global and regions.

6. To analyze Avelumab competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Avelumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Avelumab and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Avelumab.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Avelumab market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Avelumab industry.

Chapter 3: Detailed analysis of Avelumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Avelumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Avelumab in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Avelumab Industry Trends Table 2. Avelumab Industry Drivers Table 3. Avelumab Industry Opportunities and Challenges Table 4. Avelumab Industry Restraints Table 5. Global Avelumab Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Avelumab Revenue Share by Company (2021-2026) Table 7. Global Avelumab Sales Volume by Company (k units) & (2021-2026) Table 8. Global Avelumab Sales Volume Share by Company (2021-2026) Table 9. Global Avelumab Average Price (US$/unit) of Company (2021-2026) Table 10. Global Avelumab Company Ranking, (2024-2026) & (USD Million) Table 11. Global Avelumab Key Company Manufacturing Base & Headquarters Table 12. Global Avelumab Company, Product Type & Application Table 13. Global Avelumab Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Avelumab by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Type One Table 18. Significant Companies of Type Two Table 19. Global Avelumab Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Avelumab Sales Volume by Type (2021-2026) & (k units) Table 21. Global Avelumab Sales Volume by Type (2027-2032) & (k units) Table 22. Global Avelumab Sales Volume Share by Type (2021-2026) Table 23. Global Avelumab Sales Volume Share by Type (2027-2032) Table 24. Global Avelumab Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Avelumab Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Avelumab Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Avelumab Sales Value Share by Type (2021-2026) Table 28. Global Avelumab Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Merkel-cell Carcinoma Table 30. Significant Companies of Non-small Cell Lung Carcinoma (NSCLC) Table 31. Significant Companies of Others Table 32. Global Avelumab Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Avelumab Sales Volume by Application (2021-2026) & (k units) Table 34. Global Avelumab Sales Volume by Application (2027-2032) & (k units) Table 35. Global Avelumab Sales Volume Share by Application (2021-2026) Table 36. Global Avelumab Sales Volume Share by Application (2027-2032) Table 37. Global Avelumab Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Avelumab Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Avelumab Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Avelumab Sales Value Share by Application (2021-2026) Table 41. Global Avelumab Sales Value Share by Application (2027-2032) Table 42. Global Avelumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Avelumab Sales by Region (2021-2026) & (k units) Table 44. Global Avelumab Sales Market Share by Region (2021-2026) Table 45. Global Avelumab Sales by Region (2027-2032) & (k units) Table 46. Global Avelumab Sales Market Share by Region (2027-2032) Table 47. Global Avelumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Avelumab Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Avelumab Sales Value Share by Region (2021-2026) Table 50. Global Avelumab Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Avelumab Sales Value Share by Region (2027-2032) Table 52. Global Avelumab Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Avelumab Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Avelumab Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Avelumab Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Avelumab Sales by Country (2021-2026) & (k units) Table 57. Global Avelumab Sales Market Share by Country (2021-2026) Table 58. Global Avelumab Sales by Country (2027-2032) & (k units) Table 59. Global Avelumab Sales Market Share by Country (2027-2032) Table 60. Global Avelumab Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Avelumab Sales Value Market Share by Country (2021-2026) Table 62. Global Avelumab Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Avelumab Sales Value Market Share by Country (2027-2032) Table 64. Merck Company Information Table 65. Merck Business Overview Table 66. Merck Avelumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Merck Avelumab Product Portfolio Table 68. Merck Recent Development Table 69. Pfizer Company Information Table 70. Pfizer Business Overview Table 71. Pfizer Avelumab Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Pfizer Avelumab Product Portfolio Table 73. Pfizer Recent Development Table 74. Key Raw Materials Table 75. Raw Materials Key Suppliers Table 76. Avelumab Distributors List Table 77. Avelumab Customers List Table 78. Research Programs/Design for This Report Table 79. Authors List of This Report Table 80. Secondary Sources Table 81. Primary Sources List of Figures Figure 1. Avelumab Product Image Figure 2. Global Avelumab Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Avelumab Sales Value (2021-2032) & (US$ Million) Figure 4. Global Avelumab Sales (2021-2032) & (k units) Figure 5. Global Avelumab Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Avelumab Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Type I Image Figure 10. Type II Image Figure 11. Global Avelumab Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Avelumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Avelumab Sales Volume Share by Type (2021-2032) Figure 14. Global Avelumab Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Avelumab Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Avelumab Sales Value Share by Type (2021-2032) Figure 17. Merkel-cell Carcinoma Image Figure 18. Non-small Cell Lung Carcinoma (NSCLC) Image Figure 19. Others Image Figure 20. Global Avelumab Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Avelumab Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Avelumab Sales Volume Share by Application (2021-2032) Figure 23. Global Avelumab Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Avelumab Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Avelumab Sales Value Share by Application (2021-2032) Figure 26. Global Avelumab Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Avelumab Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Avelumab Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Avelumab Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Avelumab Sales Value (2021-2032) & (US$ Million) Figure 31. North America Avelumab Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Avelumab Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Avelumab Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Avelumab Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Avelumab Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Avelumab Sales Value (2021-2032) & (US$ Million) Figure 37. South America Avelumab Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Avelumab Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Avelumab Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Avelumab Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Avelumab Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Avelumab Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Avelumab Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Avelumab Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Applications
  • Merkel-cell Carcinoma
  • Non-small Cell Lung Carcinoma (NSCLC)
  • Others
Companies covered
  • Merck
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Avelumab Sales Value (2021-2032)
  4. 1.2.2 Global Avelumab Sales Volume (2021-2032)
  5. 1.2.3 Global Avelumab Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Avelumab Market Dynamics
  1. 2.1 Avelumab Industry Trends
  2. 2.2 Avelumab Industry Drivers
  3. 2.3 Avelumab Industry Opportunities and Challenges
  4. 2.4 Avelumab Industry Restraints
3 Avelumab Market by Company
  1. 3.1 Global Avelumab Company Revenue Ranking in 2025
  2. 3.2 Global Avelumab Revenue by Company (2021-2026)
  3. 3.3 Global Avelumab Sales Volume by Company (2021-2026)
  4. 3.4 Global Avelumab Average Price by Company (2021-2026)
  5. 3.5 Global Avelumab Company Ranking (2024-2026)
  6. 3.6 Global Avelumab Company Manufacturing Base and Headquarters
  7. 3.7 Global Avelumab Company Product Type and Application
  8. 3.8 Global Avelumab Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Avelumab Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Avelumab Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Avelumab Market by Type
  1. 4.1 Avelumab Type Introduction
  2. 4.1.1 By Usage
  3. 4.1.2 By Specifications
  4. 4.2 Global Avelumab Sales Volume by Type
  5. 4.2.1 Global Avelumab Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Avelumab Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Avelumab Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Avelumab Sales Value by Type
  9. 4.3.1 Global Avelumab Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Avelumab Sales Value by Type (2021-2032)
  11. 4.3.3 Global Avelumab Sales Value Share by Type (2021-2032)
5 Avelumab Market by Application
  1. 5.1 Avelumab Application Introduction
  2. 5.1.1 Merkel-cell Carcinoma
  3. 5.1.2 Non-small Cell Lung Carcinoma (NSCLC)
  4. 5.1.3 Others
  5. 5.2 Global Avelumab Sales Volume by Application
  6. 5.2.1 Global Avelumab Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Avelumab Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Avelumab Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Avelumab Sales Value by Application
  10. 5.3.1 Global Avelumab Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Avelumab Sales Value by Application (2021-2032)
  12. 5.3.3 Global Avelumab Sales Value Share by Application (2021-2032)
6 Avelumab Regional Sales and Value Analysis
  1. 6.1 Global Avelumab Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Avelumab Sales by Region (2021-2032)
  3. 6.2.1 Global Avelumab Sales by Region: 2021-2026
  4. 6.2.2 Global Avelumab Sales by Region (2027-2032)
  5. 6.3 Global Avelumab Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Avelumab Sales Value by Region (2021-2032)
  7. 6.4.1 Global Avelumab Sales Value by Region: 2021-2026
  8. 6.4.2 Global Avelumab Sales Value by Region (2027-2032)
  9. 6.5 Global Avelumab Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Avelumab Sales Value (2021-2032)
  12. 6.6.2 North America Avelumab Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Avelumab Sales Value (2021-2032)
  15. 6.7.2 Europe Avelumab Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Avelumab Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Avelumab Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Avelumab Sales Value (2021-2032)
  21. 6.9.2 South America Avelumab Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Avelumab Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Avelumab Sales Value Share by Country, 2025 VS 2032
7 Avelumab Country-level Sales and Value Analysis
  1. 7.1 Global Avelumab Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Avelumab Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Avelumab Sales by Country (2021-2032)
  4. 7.3.1 Global Avelumab Sales by Country (2021-2026)
  5. 7.3.2 Global Avelumab Sales by Country (2027-2032)
  6. 7.4 Global Avelumab Sales Value by Country (2021-2032)
  7. 7.4.1 Global Avelumab Sales Value by Country (2021-2026)
  8. 7.4.2 Global Avelumab Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Avelumab Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Avelumab Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Avelumab Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Avelumab Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Avelumab Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Avelumab Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Avelumab Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Avelumab Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Avelumab Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Avelumab Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Avelumab Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Avelumab Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Avelumab Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Avelumab Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Avelumab Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Avelumab Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Avelumab Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Avelumab Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Avelumab Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Avelumab Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Avelumab Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Avelumab Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Avelumab Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Avelumab Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Avelumab Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Avelumab Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Avelumab Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Avelumab Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Avelumab Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Avelumab Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Avelumab Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Avelumab Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Avelumab Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Avelumab Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Avelumab Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Avelumab Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Avelumab Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Avelumab Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Avelumab Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Avelumab Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Avelumab Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Avelumab Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Avelumab Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Avelumab Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Avelumab Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Avelumab Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Avelumab Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Avelumab Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Avelumab Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Avelumab Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Avelumab Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Avelumab Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Avelumab Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Avelumab Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Avelumab Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Avelumab Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Avelumab Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Avelumab Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Avelumab Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Avelumab Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Avelumab Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Avelumab Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Avelumab Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Avelumab Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Avelumab Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Avelumab Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Avelumab Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Avelumab Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Avelumab Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Avelumab Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Avelumab Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Avelumab Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Avelumab Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Avelumab Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Avelumab Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Avelumab Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Avelumab Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Avelumab Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Avelumab Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Avelumab Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Avelumab Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Avelumab Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Avelumab Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Avelumab Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Avelumab Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck Avelumab Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Avelumab Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Avelumab Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Avelumab Value Chain Analysis
  2. 9.1.1 Avelumab Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Avelumab Sales Mode & Process
  6. 9.2 Avelumab Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Avelumab Distributors
  9. 9.2.3 Avelumab Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst